Sulfadoxine (CAS 2447-57-6) Comprehensive Guide
Table of Contents
- Product Overview & Specifications
- Key Applications & Clinical Uses
- Pharmacological Profile & Mechanism
- Quality Standards & Analytical Methods
- Industrial Suppliers & Procurement Guidance
- Safety Protocols & Regulatory Compliance
1. Product Overview & Specifications
| Parameter | Value |
|---|---|
| Chemical Name | 4-Amino-N-(5,6-dimethoxy-4-pyrimidinyl)benzenesulfonamide |
| Molecular Formula | C12H14N4O4S |
| Molecular Weight | 310.33 g/mol |
| Appearance | White to off-white crystalline powder |
| Melting Point | 195-200°C |
| Solubility | Sparingly soluble in water (0.1 mg/mL), soluble in dilute acids/alkalis |
| Storage | 2-8°C protected from light |
2. Key Applications & Clinical Uses
Antimalarial Therapy: Used in combination with pyrimethamine (SP) for:
- Treatment of chloroquine-resistant Plasmodium falciparum malaria
- Intermittent preventive therapy in pregnancy (IPTp)
- Seasonal malaria chemoprevention (SMC)
Antibacterial Applications:
- Respiratory tract infections (RTIs)
- Urinary tract infections (UTIs)
- Soft tissue infections (STIs)
3. Pharmacological Profile
| Parameter | Value |
|---|---|
| Half-life | 100-230 hours |
| Protein Binding | 90-95% |
| Excretion | Renal (60-70% unchanged) |
| MIC90 | 16-32 μg/mL for sensitive P. falciparum |
4. Quality Control Standards
USP Specifications:
- Assay: ≥99.0% purity by HPLC
- Related substances: ≤0.5% total impurities
- Loss on drying: ≤1.0%
Analytical Methods:
- Identification: FTIR spectroscopy (matches USP reference spectrum)
- Potency: Reverse-phase HPLC with UV detection (254 nm)
5. Verified Suppliers & Procurement
| Supplier | Location | Specification | Contact |
|---|---|---|---|
| Hubei Yinghe Chemical | Wuhan, China | BP/USP Grade | Mr. Huang Xiaofan +86-13307112136 |
| USP Reference Standards | USA | Certified Reference Material | Order Code: Z-1626500 |
6. Safety & Regulatory Information
Contraindications:
- Hypersensitivity to sulfonamides
- Severe hepatic/renal impairment
- Porphyria patients
Adverse Effects:
- Dermatological reactions (3-5% incidence)
- Hematological changes (monitor CBC)
- Crystalluria prevention: Maintain high urine flow
Inquiry & Technical Support
For bulk orders or technical specifications:
Email: info@vivalr.com
Tel: +86-15866781826



评论
目前还没有评论。